3-bromo-5,5-dimethyl-4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxylic acid ethyl ester | 910635-63-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 3-bromo-5,5-dimethyl-4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxylic acid ethyl ester
• 英文别名: 3-bromo-5,5-dimethyl-4,5,6,7-tetrahydro-benzo[c]thiophene-1-carboxylic acid ethyl ester；ethyl 3-bromo-5,5-dimethyl-6,7-dihydro-4H-2-benzothiophene-1-carboxylate
• CAS: 910635-63-1
• 化学式: C₁₃H₁₇BrO₂S
• 分子量: 317.247
• InChiKey: XAIIKPHIMSKTHK-UHFFFAOYSA-N

物化性质

• 沸点：
  392.0±42.0 °C(Predicted)
• 密度：
  1.351±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-bromo-5,5-dimethyl-4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxylic acid ethyl ester 、 sodium methylate 在 copper(II) oxide 作用下， 以 甲醇 为溶剂， 反应 76.0h， 生成
  参考文献：
  名称：

  WO2006/100631

  摘要：

  公开号：
• 作为产物：
  描述：

  4,4-二甲基环己酮 在 草酰氯 、 乙醇 、 potassium tert-butylate 、 溴 、 sodium 、 溶剂黄146 作用下， 以 四氢呋喃 、 氯仿 、 叔丁醇 为溶剂， 反应 7.58h， 生成 3-bromo-5,5-dimethyl-4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxylic acid ethyl ester
  参考文献：
  名称：

  Novel S1P₁ Receptor Agonists - Part 2: From Bicyclo[3.1.0]hexane-Fused Thiophenes to Isobutyl Substituted Thiophenes

  摘要：

  Previously, we reported on the discovery of a novel series of bicyclo[3.1.0]hexane fused thiophene derivatives that serve as potent and selective S1P(1), receptor agonists. Here, we discuss our efforts to simplify the bicyclohexane fused thiophene head. In a first step the bicyclohexane moiety could be replaced by a simpler, less rigid cyclohexane ring without compromising the SIP receptor affinity profile of these novel compounds. In a second step, the thiophene head was simplified even further by replacing the cyclohexane ring with an isobutyl group attached either to position 4 or position S of the thiophene. These structurally much simpler headgroups again furnished potent and selective S1P(1) agonists (e.g., 87), which efficiently and dose dependently reduced the number of circulating lymphocytes upon oral administration to male Wistar rats. For several compounds discussed in this report lymphatic transport is an important route of absorption that may offer opportunities for a tissue targeted approach with minimal plasma exposure.

  DOI：

  10.1021/jm401456d

文献信息

• Hydrogenated Benzo (C) Thiophene Derivatives as Immunomodulators
  申请人：Bolli Martin

  公开号：US20080176926A1

  公开（公告）日：2008-07-24

  The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.

  该发明涉及新型噻吩衍生物，其制备以及其作为药用活性化合物的用途。这些化合物特别作为免疫抑制剂。
• HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS
  申请人：Bolli Martin

  公开号：US20100204198A1

  公开（公告）日：2010-08-12

  The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.

  该发明涉及新型噻吩衍生物，其制备及其作为药物活性化合物的用途。所述化合物特别作为免疫抑制剂。
• Hydrogenated benzo (C) thiophene derivatives as immunomodulators
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：US08039644B2

  公开（公告）日：2011-10-18

  The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.

  本发明涉及新型噻吩衍生物、其制备方法以及其作为药物活性化合物的用途。所述化合物特别作为免疫抑制剂。
• THIOPHENE, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL APPLICATION OF SAME
  申请人：CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD.

  公开号：EP3466946A1

  公开（公告）日：2019-04-10

  The present invention discloses a thiophene used as a uric acid transporter (URAT1) inhibitor and applicantion of the thiophene in preparing a pharmaceutical product for treating a disease related to abnormal uric acid levels, specifically in preparing a pharmaceutical product for treating hyperuricemia and gouty arthritis. The invention specifically relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

  本发明公开了一种用作尿酸转运体（URAT1）抑制剂的噻吩，以及该噻吩在制备治疗与尿酸水平异常有关的疾病的药品中的应用，特别是在制备治疗高尿酸血症和痛风性关节炎的药品中的应用。本发明具体涉及由式（I）代表的化合物或其药学上可接受的盐。
• Thiophene, manufacturing method thereof, and pharmaceutical application of same
  申请人：CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD.

  公开号：US10829483B2

  公开（公告）日：2020-11-10

  The present invention discloses a thiophene used as a uric acid transporter (URAT1) inhibitor and application of the thiophene in preparing a pharmaceutical product for treating a disease related to abnormal uric acid levels, specifically in preparing a pharmaceutical product for treating hyperuricemia and gouty arthritis. The invention specifically relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

  本发明公开了一种用作尿酸转运体（URAT1）抑制剂的噻吩，以及该噻吩在制备治疗与尿酸水平异常有关的疾病的药品中的应用，特别是在制备治疗高尿酸血症和痛风性关节炎的药品中的应用。本发明具体涉及一种由式（I）代表的化合物或其药学上可接受的盐。